1. Home
  2. EML vs ENGN Comparison

EML vs ENGN Comparison

Compare EML & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Company (The)

EML

Eastern Company (The)

HOLD

Current Price

$25.05

Market Cap

145.5M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.81

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EML
ENGN
Founded
1858
1999
Country
United States
Canada
Employees
N/A
82
Industry
Industrial Machinery/Components
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
145.5M
117.2M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
EML
ENGN
Price
$25.05
$1.81
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
10.9K
725.3K
Earning Date
05-12-2026
06-11-2026
Dividend Yield
1.98%
N/A
EPS Growth
185.40
N/A
EPS
0.11
N/A
Revenue
$248,970,345.00
N/A
Revenue This Year
$19.05
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$228.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.61
$1.40
52 Week High
$29.91
$12.25

Technical Indicators

Market Signals
Indicator
EML
ENGN
Relative Strength Index (RSI) 53.52 43.75
Support Level $24.84 $1.68
Resistance Level $27.19 $1.85
Average True Range (ATR) 0.80 0.09
MACD -0.07 0.01
Stochastic Oscillator 71.06 35.39

Price Performance

Historical Comparison
EML
ENGN

About EML Eastern Company (The)

The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: